Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.40 |
| ▸ | PDE4A | P27815 | 5/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30056436 | 0.93 | DRD2 (0.46) | HSD11B1FAAHDRD2DRD4HTR2A | |
| SCHEMBL30056726 | 0.93 | DRD2 (0.46) | HSD11B1FAAHDRD2DRD4HTR2A | |
| SCHEMBL30057558 | 0.91 | MCHR1 (0.48) | DRD4MCHR1 | |
| SCHEMBL30057602 | 0.85 | HSD11B1 (0.46) | HSD11B1FAAHPDE4BPDE4DPDE4C | |
| SCHEMBL21765957 | 0.82 | NTRK1 (0.40) | NTRK1 | |
| SCHEMBL30611797 | 0.80 | HDAC1 (0.45) | HSD11B1NTRK1HDAC1 | |
| SCHEMBL30056768 | 0.79 | DRD2 (0.47) | HSD11B1FAAHDRD2DRD4HTR2A | |
| SCHEMBL30057712 | 0.79 | DRD2 (0.47) | HSD11B1FAAHDRD2DRD4HTR2A | |
| SCHEMBL30056061 | 0.76 | SIGMAR1 (0.53) | HSD11B1NTRK1DRD4MCHR1 | |
| SCHEMBL26549318 | 0.74 | CACNA1G (0.42) | NTRK1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112805062-B | Imidazo [1,2-b ] pyridazines as Trk inhibitors | 博善人工智能生物科技有限公司 | 2024-06-04 | — | — | CN | claimed |
| EP-3840832-B1 | IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS | BENEVOLENTAI BIO LTD (GB) | 2023-10-11 | — | — | EP | claimed |
| US-20230149398-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | BENEVOLENTAI BIO LIMITED (GB) | 2023-05-18 | — | — | US | claimed |
| EP-4093404-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | BenevolentAI Bio Limited (GB) | 2022-11-30 | — | — | EP | claimed |
| CN-115297863-A | Topical pharmaceutical compositions comprising imidazo [1,2-b ] pyridazine compounds | 博善人工智能生物科技有限公司 | 2022-11-04 | — | — | CN | claimed |
| CN-112805062-B | Imidazo [1,2-b ] pyridazines as Trk inhibitors | 博善人工智能生物科技有限公司 | 2024-06-04 | — | — | CN | disclosed |
| EP-3840832-B1 | IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS | BENEVOLENTAI BIO LTD (GB) | 2023-10-11 | — | — | EP | disclosed |
| US-20230149398-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | BENEVOLENTAI BIO LIMITED (GB) | 2023-05-18 | — | — | US | disclosed |
| EP-4093404-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | BenevolentAI Bio Limited (GB) | 2022-11-30 | — | — | EP | disclosed |
| CN-115297863-A | Topical pharmaceutical compositions comprising imidazo [1,2-b ] pyridazine compounds | 博善人工智能生物科技有限公司 | 2022-11-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149398-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | TNK2, TNIK, TNK1 | HSD11B1 2310/4885FAAH 3328/4885PDE4B 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.